Type 1 Diabetes | Disease Landscape & Forecast | G7 | 2022
The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes already on the market for type 2 diabetes (e.g., SGLT-2 inhibitors), but a few early-phase agents (e.g., VX-880) offer a novel mechanism of action. The emphasis has shifted on the types of therapies in development for T1D; interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors is significant. The availability of biosimilar insulins is also likely to have a sizable effect on the T1D therapy market throughout the G7, resulting in an intricate interplay of physician and payer attitudes toward this treatment option.
QUESTIONS ANSWERED
- What are the drivers and constraints in the T1D market, and how will the market evolve over the forecast period?
- How are biosimilar insulins being adopted in the markets under study?
- What impact will the increasing use of insulin pumps have on market dynamics?
- How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the most clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
- How will ultra-rapid insulins, such as Novo Nordisk’s Fiasp and Eli Lilly’s Lyumjev, be incorporated into treatment in the major markets?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of T1D by country with population-specific diagnosed and drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key T1D therapies through 2031, segmented by brands / generics and epidemiological subpopulations.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select preclinical, Phase I, and Phase II products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
